Local view for "http://purl.org/linkedpolitics/eu/plenary/2010-09-22-Speech-3-196"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2010-09-22"^^xsd:date2
dcterms:Is Part Of	lp_eu:Explanations of vote2
dcterms:Language	"pt"^^xsd:language2
lpv:document identification number	"en.20100922.20.3-196"2
lpv:hasSubsequent	lp_eu:2010-09-22-Speech-3-1972
lpv:speaker	lp:Maria do Céu Patrão Neves2
lpv:spokenAs	member; EPP (2009-07-14--2014-06-30)3 unknown; Partido Social Democrata (2009-07-14--2014-06-30)3 member; Delegation for relations with Canada (2009-09-16--2014-06-30)3 member; PECH (2009-07-16--2012-01-18)3 substitute; Delegation to the ACP-EU Joint Parliamentary Assembly (2009-09-16--2014-06-30)3 substitute; AGRI (2009-07-16--2012-01-18)3
lpv:translated text	"I voted for this report as the topic it addresses – pharmacovigilance – is increasingly important in scientifically and technologically developed societies, particularly in relation to biomedical research. It strengthens the previous provisions of Regulation (EC) No 726/2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use, updating it to meet today’s needs. In this respect, I would particularly highlight the importance of cooperation between Member States. Since it can result in a much larger pool of information on adverse drug reactions, it means that rarer patterns can be picked up more quickly. In other words, it makes pharmacovigilance more effective. A related point to be emphasised is the fact that the new system proposes that all adverse drug reactions be reported to the European Medicines Agency. The broadening of criteria and the centralisation of institutions will help biomedical research and provide valuable benefits to society."@en1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph